BIAF

bioAffinity Technologies, Inc.

NasdaqAdd to watchlist

Healthcare · Diagnostics & Research

$9.43

+$0.68+7.77%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

Aug 24, 2026$9.43

+$3.61+62.03%over 1M

Session

Day range6% of range

$9.23$12.48

Fundamentals

Visualize fundamentals and more

Market cap: 49.29M
P/E ratio: -

Revenue grew −34.18% in FY2025, +43.05% slower than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Recent activity

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 22, 2026 · the newest SEC filing on file

bioAffinity Technologies, Inc. investor relations

What BIAF has filed with the SEC. This is not bioAffinity Technologies, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like bioAffinity Technologies, Inc.

Also filed under Diagnostics & Research, ranked by how closely they sit beside BIAF.

TMOThermo Fisher Scientific Inc.compare with BIAF
ILMNILLUMINA, Inc.compare with BIAF
DHRDanaher Corp.compare with BIAF
TWST

Ask about bioAffinity Technologies, Inc.

The assistant answers from what BIAF has actually filed: 5 annual reports filed with the SEC. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from BIAF's filings and figures. One a day without an account; a free account has its own, and no card.

What an account lets you do with bioAffinity Technologies, Inc.

Be told the moment a BIAF insider trades
Put bioAffinity Technologies, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
bioAffinity Technologies, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about bioAffinity Technologies, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.